CN113197837A - Folic acid-containing microecological composition and use thereof - Google Patents
Folic acid-containing microecological composition and use thereof Download PDFInfo
- Publication number
- CN113197837A CN113197837A CN202110570106.5A CN202110570106A CN113197837A CN 113197837 A CN113197837 A CN 113197837A CN 202110570106 A CN202110570106 A CN 202110570106A CN 113197837 A CN113197837 A CN 113197837A
- Authority
- CN
- China
- Prior art keywords
- weight
- parts
- acid
- folic acid
- lactobacillus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 title claims abstract description 85
- 239000000203 mixture Substances 0.000 title claims abstract description 53
- 235000019152 folic acid Nutrition 0.000 title claims abstract description 43
- 239000011724 folic acid Substances 0.000 title claims abstract description 43
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 title claims abstract description 42
- 229960000304 folic acid Drugs 0.000 title claims abstract description 42
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 41
- 241000186660 Lactobacillus Species 0.000 claims abstract description 38
- 238000000855 fermentation Methods 0.000 claims abstract description 38
- 230000004151 fermentation Effects 0.000 claims abstract description 38
- 229940039696 lactobacillus Drugs 0.000 claims abstract description 37
- 244000068988 Glycine max Species 0.000 claims abstract description 35
- 229920001202 Inulin Polymers 0.000 claims abstract description 34
- 229940029339 inulin Drugs 0.000 claims abstract description 34
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 34
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims abstract description 31
- 244000134540 Polymnia sonchifolia Species 0.000 claims abstract description 30
- 235000003406 Polymnia sonchifolia Nutrition 0.000 claims abstract description 30
- 241000186000 Bifidobacterium Species 0.000 claims abstract description 29
- 229940064062 alpha-glucan oligosaccharide Drugs 0.000 claims abstract description 28
- 239000002537 cosmetic Substances 0.000 claims abstract description 26
- 229940020356 folic acid and derivative as antianemic Drugs 0.000 claims abstract description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
- 241000894006 Bacteria Species 0.000 claims description 15
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 12
- 244000199866 Lactobacillus casei Species 0.000 claims description 12
- 235000013958 Lactobacillus casei Nutrition 0.000 claims description 12
- 229940017800 lactobacillus casei Drugs 0.000 claims description 12
- 239000006041 probiotic Substances 0.000 claims description 11
- 235000018291 probiotics Nutrition 0.000 claims description 11
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 claims description 10
- 241001608472 Bifidobacterium longum Species 0.000 claims description 9
- 241000186866 Lactobacillus thermophilus Species 0.000 claims description 9
- 229940009291 bifidobacterium longum Drugs 0.000 claims description 9
- MEANFMOQMXYMCT-OLZOCXBDSA-N 5,10-methenyltetrahydrofolic acid Chemical compound C([C@H]1CNC2=C([N+]1=C1)C(=O)N=C(N2)N)N1C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C([O-])=O)C=C1 MEANFMOQMXYMCT-OLZOCXBDSA-N 0.000 claims description 8
- MSTNYGQPCMXVAQ-KIYNQFGBSA-N 5,6,7,8-tetrahydrofolic acid Chemical compound N1C=2C(=O)NC(N)=NC=2NCC1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 MSTNYGQPCMXVAQ-KIYNQFGBSA-N 0.000 claims description 8
- 241000186012 Bifidobacterium breve Species 0.000 claims description 8
- 239000006071 cream Substances 0.000 claims description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 8
- 241001561398 Lactobacillus jensenii Species 0.000 claims description 6
- 239000000839 emulsion Substances 0.000 claims description 6
- 230000000529 probiotic effect Effects 0.000 claims description 6
- 229940015975 1,2-hexanediol Drugs 0.000 claims description 5
- 241001468229 Bifidobacterium thermophilum Species 0.000 claims description 5
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 5
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 5
- OWBTYPJTUOEWEK-UHFFFAOYSA-N butane-2,3-diol Chemical compound CC(O)C(C)O OWBTYPJTUOEWEK-UHFFFAOYSA-N 0.000 claims description 5
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 claims description 5
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 claims description 5
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 5
- 229920001285 xanthan gum Polymers 0.000 claims description 5
- 239000000230 xanthan gum Substances 0.000 claims description 5
- 235000010493 xanthan gum Nutrition 0.000 claims description 5
- 229940082509 xanthan gum Drugs 0.000 claims description 5
- 235000014655 lactic acid Nutrition 0.000 claims description 4
- 239000004310 lactic acid Substances 0.000 claims description 4
- QYNUQALWYRSVHF-OLZOCXBDSA-N (6R)-5,10-methylenetetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1C1)N)N1C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QYNUQALWYRSVHF-OLZOCXBDSA-N 0.000 claims description 3
- AUFGTPPARQZWDO-YPMHNXCESA-N 10-formyltetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1)N)N(C=O)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 AUFGTPPARQZWDO-YPMHNXCESA-N 0.000 claims description 3
- 229940105150 5-methyltetrahydrofolic acid Drugs 0.000 claims description 3
- OZRNSSUDZOLUSN-LBPRGKRZSA-N dihydrofolic acid Chemical compound N=1C=2C(=O)NC(N)=NC=2NCC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OZRNSSUDZOLUSN-LBPRGKRZSA-N 0.000 claims description 3
- ZNOVTXRBGFNYRX-ABLWVSNPSA-N levomefolic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-ABLWVSNPSA-N 0.000 claims description 3
- 239000003921 oil Substances 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- 238000003287 bathing Methods 0.000 claims 1
- 229940014144 folate Drugs 0.000 claims 1
- 206010000496 acne Diseases 0.000 description 39
- 208000002874 Acne Vulgaris Diseases 0.000 description 37
- 210000003491 skin Anatomy 0.000 description 33
- 230000000052 comparative effect Effects 0.000 description 30
- 230000002757 inflammatory effect Effects 0.000 description 28
- 238000012360 testing method Methods 0.000 description 25
- 206010040882 skin lesion Diseases 0.000 description 23
- 231100000444 skin lesion Toxicity 0.000 description 23
- 230000000694 effects Effects 0.000 description 21
- 239000003814 drug Substances 0.000 description 11
- 210000003780 hair follicle Anatomy 0.000 description 10
- 238000002156 mixing Methods 0.000 description 10
- 229940079593 drug Drugs 0.000 description 8
- 230000008439 repair process Effects 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 7
- 230000004060 metabolic process Effects 0.000 description 7
- 208000020154 Acnes Diseases 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 235000013406 prebiotics Nutrition 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 210000002374 sebum Anatomy 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 239000002253 acid Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 210000001732 sebaceous gland Anatomy 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- 240000008892 Helianthus tuberosus Species 0.000 description 3
- 235000003230 Helianthus tuberosus Nutrition 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 206010037888 Rash pustular Diseases 0.000 description 3
- 208000028990 Skin injury Diseases 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 230000000172 allergic effect Effects 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 208000031513 cyst Diseases 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 239000000686 essence Substances 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 229960003444 immunosuppressant agent Drugs 0.000 description 3
- 239000003018 immunosuppressive agent Substances 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 208000020016 psychiatric disease Diseases 0.000 description 3
- 208000029561 pustule Diseases 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 229920000310 Alpha glucan Polymers 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 229920000832 Cutin Polymers 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 208000017701 Endocrine disease Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010054107 Nodule Diseases 0.000 description 2
- 206010033733 Papule Diseases 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 239000002390 adhesive tape Substances 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000003325 follicular Effects 0.000 description 2
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 2
- 229940107187 fructooligosaccharide Drugs 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 239000004519 grease Substances 0.000 description 2
- 239000008236 heating water Substances 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000000415 inactivating effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 2
- 230000037311 normal skin Effects 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 239000002417 nutraceutical Substances 0.000 description 2
- 235000021436 nutraceutical agent Nutrition 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 229940127234 oral contraceptive Drugs 0.000 description 2
- 239000003539 oral contraceptive agent Substances 0.000 description 2
- 230000004792 oxidative damage Effects 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 230000008591 skin barrier function Effects 0.000 description 2
- 230000037380 skin damage Effects 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 230000037072 sun protection Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 208000014085 Chronic respiratory disease Diseases 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 241000186427 Cutibacterium acnes Species 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 206010016880 Folate deficiency Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 241001468157 Lactobacillus johnsonii Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 206010042276 Subacute endocarditis Diseases 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003571 Vitamin B5 Natural products 0.000 description 1
- 241000863026 Vitreoscilla filiformis Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 230000004099 anaerobic respiration Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000003670 easy-to-clean Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- -1 fatty acid esters Chemical class 0.000 description 1
- 230000004992 fission Effects 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229940117681 interleukin-12 Drugs 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000008558 metabolic pathway by substance Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000002366 mineral element Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229940055019 propionibacterium acne Drugs 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical group O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 244000005714 skin microbiome Species 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 208000008467 subacute bacterial endocarditis Diseases 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000009492 vitamin B5 Nutrition 0.000 description 1
- 239000011675 vitamin B5 Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/85—Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Abstract
The invention discloses a folic acid-containing microecological composition which comprises the following components in parts by weight: 0.01-0.3 part of folic acid and derivatives thereof; 0.09-2.7 parts of soybean fermentation product extract; 0.05-1.5 parts of alpha-glucan oligosaccharide; 0.03-0.9 part of yacon root juice; 0.01-0.3 part of inulin; 0.001-0.03 parts of lactobacillus; 0.001-0.03 part of bifidobacterium. The invention also discloses a cosmetic comprising the folic acid-containing micro-ecological composition.
Description
Technical Field
The invention relates to the technical field of cosmetics, and particularly relates to a folic acid-containing microecological composition and application thereof.
Background
Acne, also known as acne, is a chronic inflammatory skin disease that manifests itself well in the hair follicles and sebaceous glands of the face, chest and back. The typical development process is as follows: affected by factors such as male hormone and the like, sebum secretion is disordered, and sebaceous gland grease is exuberant in secretion; secondly, the hair follicle is blocked, sebum cannot be normally discharged, a keratotic plug is formed, and acne is generated; bacteria proliferation, especially the increase of the number of propionibacterium acnes, decomposes sebum, releases irritant free fatty acid, initiates inflammatory reaction, and generates pimples and pustules; and fourthly, foreign matters such as inflammatory substances and the like are accumulated continuously, foreign matter sample reaction is generated, deep inflammation around hair follicles is caused, and nodules and cysts are generated. Wherein, skin damage in the fourth stage: papules, pustules, nodules and cysts are inflammatory skin lesions, can be treated by methods of bacteriostasis, anti-inflammation and the like, and have obvious effect; however, acne at the second stage is non-inflammatory skin lesions and is difficult to treat by methods such as bacteriostasis, anti-inflammation and the like. At present, the research and development of acne-removing cosmetics always focuses on the repair of inflammatory skin lesions, acne is often ignored, the acne becomes a state which is common and long-standing on the face of a consumer, and the acne-removing cosmetics are difficult to puzzle for most people.
Aiming at non-inflammatory skin lesions of acne, the current cosmetic nursing measures are mainly to adopt cosmetics containing salicylic acid, fruit acid, azelaic acid, vitamin A acid and the like or to use a guide-out film with strong tearing capacity to strip off cutin, reduce the blockage of hair follicles and normally discharge sebum. However, such cosmetics often cause dry, red, itchy and even allergic skin of consumers, and acne is easy to recur after the use is stopped, thereby treating symptoms and not root causes.
The microecological technology is a new technology for nursing pox at present, and the effects of repairing skin microecological barriers, inhibiting bacteria and resisting inflammation are achieved through external use of prebiotics, prebiotics and probiotics; meanwhile, the advantages of mildly regulating the skin state and enhancing the skin resistance are widely accepted by the market. But the traditional Chinese medicine composition has long generation effect time, has obvious effect on inflammatory skin lesions and has poor effect on non-inflammatory skin lesions and acnes, and is difficult to meet the requirements of most consumers.
Disclosure of Invention
Based on this, aiming at the fact that no product which is practical and effective for non-inflammatory skin lesions and acnes and inflammatory skin lesions, treats both symptoms and root causes, is safe and mild in the traditional technology, a folic acid-containing microecological composition and application thereof are provided.
A folic acid-containing microecological composition comprises the following components in parts by weight:
0.01-0.3 part of folic acid and derivatives thereof;
0.09-2.7 parts of soybean fermentation product extract;
0.05-1.5 parts of alpha-glucan oligosaccharide;
0.03-0.9 part of yacon root juice;
0.01-0.3 part of inulin;
0.001-0.03 parts of lactobacillus;
0.001-0.03 part of bifidobacterium.
In some of these embodiments, the folic acid and derivatives thereof are selected from one or more of folic acid, dihydrofolic acid, tetrahydrofolic acid, 5-formyltetrahydrofolic acid, 10-formyltetrahydrofolic acid, 5, 10-methenyltetrahydrofolic acid, 5, 10-methylenetetrahydrofolic acid, and 5-methyltetrahydrofolic acid.
In some of these embodiments, the soy fermentation product extract is selected from a soy fermentation product extract fermented with bacillus and/or lactobacillus.
In some of these embodiments, the lactobacillus is an inactivated strain selected from one or more of lactobacillus thermophilus, lactobacillus casei, and lactobacillus jensenii.
In some of these embodiments, the bifidobacterium is an inactivated strain selected from one or more of bifidobacterium longum, bifidobacterium breve, bifidobacterium thermophilum, and bifidobacterium ovorans.
In some embodiments, the folic acid-containing microecological composition comprises, by weight, 0.25-0.35 parts of tetrahydrofolic acid, 2.6-2.8 parts of lactobacillus fermented soybean fermentation product extract, 1.4-1.6 parts of alpha-glucan oligosaccharide, 0.8-1.0 part of jerusalem artichoke root juice, 0.25-0.35 part of inulin, 0.025-0.035 part of lactobacillus casei, and 0.025-0.035 part of bifidobacterium breve.
In some embodiments, the folic acid-containing microecological composition comprises, by weight, 0.08-0.12 parts of folic acid, 0.8-1.0 parts of a bacillus fermented soybean fermentation product extract, 0.4-0.6 parts of alpha-glucan oligosaccharide, 0.25-0.35 parts of yacon root juice, 0.08-0.12 parts of inulin, 0.008-0.012 parts of lactobacillus casei and 0.008-0.012 parts of bifidobacterium longum.
In some embodiments, the folic acid-containing micro-ecological composition comprises 0.18-0.22 part of 5, 10-methenyltetrahydrofolic acid, 1.3-1.7 parts of lactobacillus fermented soybean fermentation product extract, 0.8-1.2 parts of alpha-glucan oligosaccharide, 0.5-0.7 part of yacon root juice, 0.18-0.22 part of inulin, 0.018-0.022 part of lactobacillus thermophilus and 0.018-0.022 part of bifidobacterium ovorans.
A cosmetic is cream, emulsion, water, oil, bath product or washing and caring product prepared by adding the above folic acid-containing microecological composition.
In some embodiments, the cosmetic is essence water, and the essence water comprises, by weight, 0.15-0.25 parts of hydroxyethyl cellulose, 0.10-0.20 parts of xanthan gum, 2.5-3.5 parts of methyl propylene glycol, 0.35-0.45 parts of p-hydroxyacetophenone, 0.45-0.55 parts of 1, 2-hexanediol, the folic acid-containing microecological composition, and water.
The invention unexpectedly produces excellent effect of removing noninflammatory skin lesions and acnes by combining folic acid and derivatives thereof, soybean fermentation product extract, alpha-glucan oligosaccharide, yacon root juice, inulin, lactobacillus and bifidobacterium in a reasonable proportion. Can act on the pilosebaceous unit, and has synergistic effect, and can improve the environment of acne, maintain normal metabolism of the pilosebaceous unit, remove noninflammatory acne, and reduce subsequent inflammatory skin injury. Meanwhile, the repair time of inflammatory skin lesions can be greatly shortened, skin barriers can be repaired, and the stable state of skin can be maintained. The invention is safe and has no side effect, can be prepared into cosmetics in various dosage forms, is not limited to face cleaning, water, emulsion, cream, essence, gel, foundation make-up, sun protection and the like, and can be used for daily care of any skin, especially for the care of acne muscles.
Detailed Description
In order that the invention may be more fully understood, reference will now be made to the following description. The present invention may be embodied in many different forms and is not limited to the embodiments described herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The terminology used in the description of the invention herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. As used herein, the term "and/or" includes any and all combinations of one or more of the associated listed items.
The embodiment of the invention provides a folic acid-containing microecological composition which comprises the following components in parts by weight:
0.01-0.3 part of folic acid and derivatives thereof;
0.09-2.7 parts of soybean fermentation product extract;
0.05-1.5 parts of alpha-glucan oligosaccharide;
0.03-0.9 part of yacon root juice;
0.01-0.3 part of inulin;
0.001-0.03 parts of lactobacillus;
0.001-0.03 part of bifidobacterium.
The invention unexpectedly produces excellent effect of removing noninflammatory skin lesions and acnes by combining folic acid and derivatives thereof, soybean fermentation product extract, alpha-glucan oligosaccharide, yacon root juice, inulin, lactobacillus and bifidobacterium in a reasonable proportion. Can act on the pilosebaceous unit, and has synergistic effect, and can improve the environment of acne, maintain normal metabolism of the pilosebaceous unit, remove noninflammatory acne, and reduce subsequent inflammatory skin injury. Meanwhile, the repair time of inflammatory skin lesions can be greatly shortened, skin barriers can be repaired, and the stable state of skin can be maintained. The invention is safe and has no side effect, can be prepared into cosmetics in various dosage forms, is not limited to face cleaning, water, emulsion, cream, essence, gel, foundation make-up, sun protection and the like, and can be used for daily care of any skin, especially for the care of acne muscles.
Folic acid is a complex of vitamin B, and is found in green vegetables and fruits, citrus, yeast, liver, etc. Plays an important role in the one-carbon mechanism of DNA and RNA synthesis, and is involved in many important biochemical processes. Mainly comprises that firstly, the synthesis of purine and thymine is participated in, and DNA and RNA are further synthesized; ② the amino acid is involved in the mutual conversion, and is used as a carrier of a one-carbon unit, such as the interchange of serine and glycine, and the interchange of histidine decomposed into glutamic acid and homocysteine and methionine; ③ the synthesis of hemoglobin and important methyl compounds, such as epinephrine, choline and creatine. The skin, an important component of the whole body of the human body, participates in the metabolism of substances including sugar, fat, water, electrolytes, proteins, etc. The normal metabolism of human skin needs to be maintained by relying on continued epidermal cell proliferation and differentiation. Studies have shown that many skin diseases and even skin cancers are closely related to folate deficiency. It can prevent and repair DNA damage, and is the source of eliminating wrinkles and resisting skin aging.
In the invention, folic acid and derivatives thereof can promote the differentiation, maturation and shedding of keratinocytes of hair follicle parts, reduce the formation of keratotic plugs, improve the condition of hair follicle blockage and maintain the normal metabolism of hair follicle units in hair follicle sebaceous gland units; meanwhile, the skin care product can resist daily skin oxidative damage and maintain normal skin metabolism.
In some embodiments, the folic acid and derivatives thereof are selected from one or more of folic acid, dihydrofolic acid, tetrahydrofolic acid, 5-formyltetrahydrofolic acid, 10-formyltetrahydrofolic acid, 5, 10-methenyltetrahydrofolic acid, 5, 10-methylenetetrahydrofolic acid, and 5-methyltetrahydrofolic acid.
The soybean fermentation product extract belongs to post-production, and is a natural component extracted from metabolites generated by soybeans after being fermented by a specific strain. Is rich in bioactive factors such as plant collagen, small molecular soybean polypeptide, various amino acids, lactic acid, isoflavone, multivitamins, coenzyme Q10, superoxide dismutase (SOD), saponin, etc. Can be selected from soybean fermentation products fermented by bacillus or lactobacillus. The soybean fermentation product extract is a natural component extracted from a metabolite produced by fermenting soybeans with a specific strain. Can enhance skin moisture retention effect, promote collagen activation, and make skin cells full of vitality. The soybean fermentation product extract is commercially available and available from soyama corporation of korea.
In the invention, the soybean fermentation product extract can regulate and control the grease secretion of the sebaceous unit in the pilosebaceous unit and inhibit the release of inflammatory factors; meanwhile, the skin care product provides nutrient substances for the stratum corneum of the skin and moistens the skin.
In some embodiments, the soy fermentation product extract is selected from a soy fermentation product extract fermented with bacillus and/or lactobacillus.
The alpha-glucan oligosaccharide belongs to prebiotics, is available on the market and can be purchased from the company of Xianting in France. Alpha-glucan oligosaccharides are prebiotics obtained by enzymatic synthesis of natural sugars (sucrose and maltose). It is a bioselective substrate that protects and stimulates the skin flora of beneficial microorganisms, but not pathogens and undesirable flora. It can also stimulate keratinocyte to release antibacterial peptide, and has certain moisturizing effect.
In the invention, the alpha-glucan oligosaccharide can regulate and control the beneficial microbial activity of the sebaceous unit in the pilosebaceous unit, reduce the decomposition of pathogenic bacteria on sebum and further reduce the release of inflammatory factors.
The yacon root juice belongs to prebiotics. The yacon root juice is also called yacon or yacon and contains fructose, glucose, sucrose, fructo-oligosaccharide, starch, inulin, a small amount of cellulose, vitamins, mineral elements and the like, wherein the inulin and the fructo-oligosaccharide account for 67 percent of dry matter of the yacon juice, can resist oxidation, eliminate free radicals, have the effects of clearing liver, detoxifying, reducing pathogenic fire and lowering blood pressure, and are effective substances for preventing and treating acne and pimples.
According to the invention, the yacon root juice can selectively promote the colonization of beneficial bacteria such as lactobacillus, bifidobacterium, streptococcus and the like, inhibit the growth of harmful bacteria and improve the flora environment of the pilosebaceous unit; meanwhile, the folic acid can be promoted to be utilized, and the normal metabolism of the follicular unit and the sebaceous gland unit can be maintained.
Inulin belongs to prebiotics. Inulin can be directly used in various cosmetics, and can also be made into fatty acid esters. Inulin can stabilize emulsion, has good dispersibility, spreadability and thickening effect, can inhibit foam, is easy to clean, and has good skin feel; can be used in powder cosmetic for smoothing skin; inulin can be absorbed by skin, and has antioxidant and nutritional effects.
According to the invention, the inulin can protect the skin micro-ecological environment from being damaged by the stimulating components such as preservatives, essence, surfactants and the like in the formula, optimize the micro-ecological barrier and have excellent moisturizing effect; at the same time, oxidative damage to hair follicle keratinocytes can be reduced.
The lactobacillus is a probiotic. Lactobacillus is a generic name for various bacteria that can decompose sugars such as glucose into lactic acid. Lactobacillus is a bacillus-free bacterium, and belongs to gram-positive bacteria. Single, double or short chain arrangement, anaerobic respiration. The lactobacillus has stronger capability of metabolizing carbohydrate to produce acid, can synthesize glucan and heteropolysaccharide, and can ferment saccharide to produce lactic acid or other acid substances. The lactobacillus is widely distributed in the nature, and some strains are one of normal flora of oral cavity, intestinal tract and vagina of human and animals, rarely cause diseases, are basically harmless to human except for causing subacute bacterial endocarditis very occasionally.
In the invention, the lactobacillus is an inactivated strain, and can provide complete effective components of the strain and play the role of active lactobacillus while not influencing the number of microorganisms in cosmetics. The lactobacillus has the effects of promoting the proliferation of beneficial bacteria, keeping the weak acidity of the skin, inhibiting the proliferation of harmful bacteria and improving the balance of the overall skin microecology.
The inactivated probiotics can kill harmful flora, promote the growth of beneficial bacteria, improve the immunity of the skin, repair the skin, consolidate the barrier and achieve the effect of micro-ecological skin care in multiple directions. The target cells for the immune activation of peptidoglycan, polysaccharide and teichoic acid in the inactivated probiotic cell wall components and the components of metabolites (vitamins, free amino acids and the like) of the inactivated probiotic cell wall components are mainly macrophages and B lymphocytes. The inactivated probiotics can activate macrophages to enhance the phagocytic function of the macrophages, and secrete various effector molecules with the function of killing tumors, such as soluble alpha tumor necrosis factor, interleukin 6, interleukin 12, interferon-gamma and the like, wherein the tumor necrosis factor has the effect of killing cancer cells and causes the bleeding and necrosis of tumors. The interleukin is also an important immune active factor, and participates in inflammatory reaction to regulate the body to have immune function. Meanwhile, the inactivated probiotics can also induce B lymphocytes to secrete various antibodies and enhance the killing function of cytotoxic T lymphocytes and natural killer cells.
The lactobacillus is dead bacteria powder obtained by inactivating, centrifuging, extracting, coating and drying lactobacillus bacteria liquid. Wherein, the cell number of the lactobacillus can be: 109~1014cfu/g。
In some embodiments, the lactobacillus is selected from one or more of lactobacillus thermophilus, lactobacillus casei and lactobacillus jensenii.
The bifidobacteria belong to the group of probiotics. The genus bifidobacterium is a gram-positive, immotile, rod-shaped, sometimes bifurcated, strictly anaerobic genus of bacteria with cells at one end, which is found in the human and animal habitat in the digestive tract, vagina and oral cavity. Bacteria of the genus bifidobacterium are one of the important members of the human and animal intestinal flora.
In the invention, the bifidobacterium is an inactivated strain, and can provide complete effective components of the strain and play the role of active bifidobacterium while not influencing the number of microorganisms in cosmetics. The bifidobacterium can inhibit the growth of harmful bacteria on the surface of the skin, reduce the occurrence of inflammatory reaction and enhance the resistance of the skin; meanwhile, the mild stripping of the hair follicle cutin suppository can be promoted, and the internal environment of the follicular unit is purified.
In some embodiments, the bifidobacterium is an inactivated strain selected from one or more of bifidobacterium longum, bifidobacterium breve, bifidobacterium thermophilum, and bifidobacterium ovorans.
The bifidobacterium is prepared by inactivating, centrifuging, extracting, coating,Drying to obtain dead bacteria powder. Wherein, the number of the somatic cells of the bifidobacterium can be: 109~1014cfu/g。
In some preferred embodiments, the folic acid-containing microecological composition comprises, by weight, 0.25 to 0.35 parts of tetrahydrofolic acid, 2.6 to 2.8 parts of lactobacillus fermented soybean fermentation product extract, 1.4 to 1.6 parts of alpha-glucan oligosaccharide, 0.8 to 1.0 part of jerusalem artichoke root juice, 0.25 to 0.35 part of inulin, 0.025 to 0.035 parts of lactobacillus casei, and 0.025 to 0.035 parts of bifidobacterium breve.
In some preferred embodiments, the folic acid-containing microecological composition comprises, by weight, 0.08-0.12 parts of folic acid, 0.8-1.0 parts of a bacillus fermented soybean fermentation product extract, 0.4-0.6 parts of alpha-glucan oligosaccharide, 0.25-0.35 parts of yacon root juice, 0.08-0.12 parts of inulin, 0.008-0.012 parts of lactobacillus casei, and 0.008-0.012 parts of bifidobacterium longum.
In some preferred embodiments, the folic acid-containing micro-ecological composition comprises, by weight, 0.18-0.22 parts of 5, 10-methenyltetrahydrofolic acid, 1.3-1.7 parts of lactobacillus fermented soybean fermentation product extract, 0.8-1.2 parts of alpha-glucan oligosaccharide, 0.5-0.7 parts of yacon root juice, 0.18-0.22 parts of inulin, 0.018-0.022 parts of lactobacillus thermophilus, and 0.018-0.022 parts of bifidobacterium ovorans.
The embodiment of the invention also provides a cosmetic which is cream, emulsion, water, oil, bath product or washing product prepared in a general way, and contains the folic acid-containing microecological composition.
In some embodiments, the cosmetic is serum. The essence water comprises, by weight, 0.15-0.25 part of hydroxyethyl cellulose, 0.10-0.20 part of xanthan gum, 2.5-3.5 parts of methyl propylene glycol, 0.35-0.45 part of p-hydroxyacetophenone, 0.45-0.55 part of 1, 2-hexanediol, the folic acid-containing microecological composition and water.
The following are specific examples
Examples 1 to 9
A folic acid-containing microecological composition has the following formula:
example 1
0.01 weight part of folic acid, 0.09 weight part of bacillus fermented soybean fermentation product extract, 0.05 weight part of alpha-glucan oligosaccharide, 0.03 weight part of yacon root juice, 0.01 weight part of inulin, 0.001 weight part of lactobacillus thermophilus and 0.001 weight part of bifidobacterium longum are uniformly mixed at room temperature to prepare the microecological composition 1.
Example 2
Taking 0.3 weight part of tetrahydrofolic acid, 2.7 weight parts of lactobacillus fermented soybean fermentation product extract, 1.5 weight parts of alpha-glucan oligosaccharide, 0.9 weight part of yacon root juice, 0.3 weight part of inulin, 0.03 weight part of lactobacillus casei and 0.03 weight part of bifidobacterium breve, and uniformly mixing at room temperature to prepare the microecological composition 2.
Example 3
Taking 0.05 part by weight of 5-formyl tetrahydrofolic acid, 0.3 part by weight of bacillus fermented soybean fermentation product extract, 0.2 part by weight of alpha-glucan oligosaccharide, 0.1 part by weight of yacon root juice, 0.05 part by weight of inulin, 0.005 part by weight of lactobacillus jensenii and 0.005 part by weight of bifidobacterium thermophilum, and uniformly mixing at room temperature to prepare the microecological composition 3.
Example 4
0.2 part of 5, 10-methenyltetrahydrofolic acid, 1.5 parts of lactobacillus fermented soybean fermentation product extract, 1 part of alpha-glucan oligosaccharide, 0.6 part of yacon root juice, 0.2 part of inulin, 0.02 part of lactobacillus thermophilus and 0.02 part of bifidobacterium ovorans are uniformly mixed at room temperature to prepare the microecological composition 4.
Example 5
0.1 part by weight of folic acid, 0.9 part by weight of bacillus fermented soybean fermentation product extract, 0.5 part by weight of alpha-glucan oligosaccharide, 0.3 part by weight of yacon root juice, 0.1 part by weight of inulin, 0.01 part by weight of lactobacillus casei and 0.01 part by weight of bifidobacterium longum are uniformly mixed at room temperature to prepare the microecological composition 5.
Example 6
Taking 0.3 weight part of tetrahydrofolic acid, 0.09 weight part of lactobacillus fermented soybean fermentation product extract, 0.05 weight part of alpha-glucan oligosaccharide, 0.03 weight part of yacon root juice, 0.01 weight part of inulin, 0.001 weight part of lactobacillus jensenii and 0.001 weight part of bifidobacterium breve, and uniformly mixing at room temperature to prepare the microecological composition 6.
Example 7
0.01 part by weight of 5-formyl tetrahydrofolic acid, 2.7 parts by weight of bacillus fermented soybean fermentation product extract, 0.05 part by weight of alpha-glucan oligosaccharide, 0.03 part by weight of yacon root juice, 0.01 part by weight of inulin, 0.001 part by weight of lactobacillus thermophilus and 0.001 part by weight of bifidobacterium thermophilum are uniformly mixed at room temperature to prepare the microecological composition 7.
Example 8
0.01 part by weight of 5, 10-methenyltetrahydrofolic acid, 0.09 part by weight of lactobacillus fermented soybean fermentation product extract, 1.5 parts by weight of alpha-glucan oligosaccharide, 0.9 part by weight of yacon root juice, 0.3 part by weight of inulin, 0.001 part by weight of lactobacillus casei and 0.001 part by weight of bifidobacterium ovoid are uniformly mixed at room temperature to prepare the microecological composition 8.
Example 9
0.01 part by weight of folic acid, 0.09 part by weight of bacillus fermented soybean fermentation product extract, 0.05 part by weight of alpha-glucan oligosaccharide, 0.03 part by weight of yacon root juice, 0.01 part by weight of inulin, 0.03 part by weight of lactobacillus jensenii and 0.03 part by weight of bifidobacterium longum are uniformly mixed at room temperature to prepare the microecological composition 9.
Comparative examples 1 to 7
Comparative example 1
Comparative example 1 differs from example 5 in that folic acid and its derivatives are replaced with equal parts by weight of vitamin B5. And uniformly mixing at room temperature to prepare the microecological composition 10.
Comparative example 2
Comparative example 2 differs from example 5 in that the soybean fermentation product extract was replaced with an equal weight part of the yeast for secondary fission. And uniformly mixing at room temperature to prepare the microecological composition 11.
Comparative example 3
Comparative example 3 differs from example 5 in that the alpha-glucan oligosaccharides were replaced with equal parts by weight of xylose. And uniformly mixing at room temperature to prepare the microecological composition 12.
Comparative example 4
Comparative example 4 is different from example 5 in that the jerusalem artichoke root juice is replaced with raffinose in an equal weight part. And uniformly mixing at room temperature to obtain the microecological composition 13.
Comparative example 5
Comparative example 5 differs from example 5 in that inulin is replaced with equal parts by weight of dextran. And uniformly mixing at room temperature to prepare the microecological composition 14.
Comparative example 6
Comparative example 6 is different from example 5 in that lactobacillus was replaced with lactobacillus johnsonii in equal parts by weight. And uniformly mixing at room temperature to prepare the microecological composition 15.
Comparative example 7
Comparative example 7 differs from example 5 in that bifidobacteria were replaced with equal parts by weight of Vitreoscilla filiformis. And uniformly mixing at room temperature to prepare the microecological composition 16.
Application examples 1 to 9
The microecological compositions 1 to 9 of examples 1 to 9 were added to serum to obtain acne-removing serum. And testing the safety and the efficacy of the added acne removing essence.
The preparation method of the acne removing essence comprises the following steps:
1. heating water (the total formula is calculated by 100 weight parts, the water amount after removing other components), 0.2 weight part of hydroxyethyl cellulose, 0.15 weight part of xanthan gum, 3 weight parts of methyl propylene glycol, 0.4 weight part of p-hydroxyacetophenone and 0.5 weight part of 1, 2-hexanediol to 80 ℃, and stirring for dissolving;
2. cooling to 45 ℃, respectively adding 1-9 micro-ecological compositions, and stirring for dissolving;
3. and cooling to 35 ℃, defoaming and filtering to obtain application examples 1-9.
Application comparative examples 1 to 7
The microecological compositions 10 to 16 of comparative examples 1 to 7 were added to the essence water to obtain the acne-removing essence water. And testing the safety and the efficacy of the added acne removing essence.
The preparation method of the acne removing essence water comprises the following steps (when the microecological composition does not contain a certain component, the component is not added in the preparation process):
1. heating water (the total formula is calculated by 100 weight parts, the water amount after removing other components), 0.2 weight part of hydroxyethyl cellulose, 0.15 weight part of xanthan gum, 3 weight parts of methyl propylene glycol, 0.4 weight part of p-hydroxyacetophenone and 0.5 weight part of 1, 2-hexanediol to 80 ℃, and stirring for dissolving;
2. cooling to 45 ℃, respectively adding 10-16 micro-ecological compositions, and stirring for dissolving;
3. and cooling to 35 ℃, defoaming and filtering to obtain application comparative examples 1-7.
Application comparative example 8: the commercially available acne-removing essence water containing 2% of salicylic acid (containing no folic acid and its derivatives, soybean fermentation product extract, alpha-glucan oligosaccharide, yacon root juice, inulin, lactobacillus and bifidobacterium in the examples).
Application comparative example 9: the commercially available acne-removing essence containing 2% lactobacillus fermentation product (not containing folic acid and its derivatives, soybean fermentation product extract, alpha-glucan oligosaccharide, yacon root juice, inulin, lactobacillus and bifidobacterium in the examples) specially developed for inflammatory skin lesions.
Safety
Skin occlusion patch test:
510 volunteers meeting the enrollment criteria were selected for the trial and randomized into 17 groups of 30 individuals each.
Inclusion volunteer criteria were: 1) the age is between 15 and 60 years old, and both men and women can use the health care tea; 2) no serious diseases, no immunodeficiency or autoimmune diseases, and no skin treatment and beauty treatment on the tested part; 3) no active allergic disease; 4) the tested part is not applied with any anti-inflammatory drugs in the last two months; 5) one week later with antihistamine or one month later without immunosuppressant. 6) Those who did not perform the patch test within a month.
Exclusion criteria: 1) pregnant or lactating women; 2) patients with severe diseases of heart, lung, cerebral vessels, liver, kidney and hemopoietic system and mental disease; 3) patients suffering from asthma or other chronic respiratory diseases are being treated.
Abort and exit criteria: during the test, the test sample was not applied as required or the record was not recalled as required.
All volunteers need to sign their informed consent. The back of all spot testers is marked with sample numbers, and an equal amount of acne removing essence water is added, a control group is a blank group without any substances, 0.03g of sample is placed in a medicine chamber of a spot test adhesive tape, the spot test adhesive tape with the sample is immediately and longitudinally pasted on normal skin of a left forearm from the lower part, and simultaneously the medicine chamber is lightly pressed one by one to expel air, and the test substances are uniformly distributed. The test site is marked for easy observation. Three groups of parallel lines and a blank group are set, the patch is applied once every 24 hours, and the patch is uncovered for a second half hour, and then the examination is performed according to the grading standard. The patch test was performed 6 times in total, and on day 6 after completion of the skin application, additional examination was performed to observe delayed reactions.
The criteria for the skin irritation test are shown in Table 1. The results are shown in tables 2 and 3.
TABLE 1 grading Standard of adverse skin reactions in the closed Patch test
TABLE 2 skin occlusion Patch test example results
TABLE 3 comparative results of skin-occlusive patch test
The results show that no adverse reaction occurs in human bodies in the application examples 1-9, and the safety is high. As can be seen from comparison between application examples 1-9 and application comparative examples 1-8, the reasonable proportion of the specific components can improve the safety of the product.
(II) evaluation of efficacy of removing noninflammatory skin lesions and acnes
540 volunteers meeting the enrollment criteria were selected for the trial and all volunteers were randomly divided into 18 groups of 30 individuals each. The application examples 1-9, the application comparative examples 1-8 and the blank essence water without the micro-ecological composition are respectively tried on all groups of volunteers.
Inclusion volunteer criteria were: the age is 20-45 years old, and the nature is not limited; people with oily and mixed skin and face with obvious noninflammatory skin damage and acne; hormone drugs and immunosuppressants have not been used in the last month; the tested part does not participate in other clinical testers at present or in nearly 30 days; can be matched with testers well; the system can read and understand all contents of the informed consent and voluntarily sign the informed consent; during the test period, the consent was not to use any cosmetics, drugs and nutraceuticals that have an impact on the outcome.
Exclusion criteria: open wound or erosion face at the acne affected part; those with high allergic constitution; those with a history of cosmetic allergy; a female who is pregnant, lactating, or intended to be pregnant during the test; severe center of gravity, liver and kidney function damage and severe immunologic hypofunction; those with mental disorders, severe endocrine disorders, and oral contraceptives; the patients who participate in the drug clinical testers or other testers within 30 days, or the patients who have systemic drugs which have influence on the test results within about 1 week; those who had oral and topical cosmetic products within 2 weeks that may have an effect on the outcome of the test; the investigator considered not appropriate for attending the investigator.
Abort and exit criteria: smearing the tested sample or recording the revisit according to the requirement during the test period; has serious diseases or serious adverse reactions during the use period.
After the volunteers cleaned the face in the morning and evening every day, the acne removing effect was self-evaluated after continuous use for 4 weeks and 8 weeks using the corresponding acne removing essence water of each group. The evaluation scale was: the effect is obvious, the effect is general, no effect exists, four grades of deterioration appear, and the number of cured people is counted.
The results are shown in Table 4 below.
TABLE 4 therapeutic Effect of non-inflammatory skin lesions on acne
As can be seen from the data in Table 4, after the application examples 1-9 are used, noninflammatory skin lesions and acnes of the volunteers are obviously improved, the cure rate is high, and after the continuous application for 8 weeks, the cure rate reaches 100%. The number of cured patients in examples 2, 4 and 5 after 4 weeks of continuous use can reach more than 20.
As can be seen from comparison between application examples 1-9 and application comparative examples 1-7, any component in the formula of the acne removing cream cannot achieve an excellent acne removing effect, particularly, the acne removing cream is low in cure rate, can only achieve an improved effect, and is difficult to radically cure. It is exactly indicated that the components of the invention can be synergistic and treat both principal and secondary aspect of disease. As can be seen from comparison between application examples 1-9 and application comparative example 8 and blank essence water, the acne cream can reduce conversion from acne to inflammatory skin lesions and maintain normal metabolism of pilosebaceous units.
(III) evaluation of inflammatory skin lesion repair efficacy
540 volunteers meeting the enrollment criteria were selected for the trial and all volunteers were randomly divided into 18 groups of 30 individuals each. Application examples 1-9, application comparative examples 1-7, application comparative example 9 and blank essence water without the micro-ecological composition are respectively tried on all groups of volunteers.
Inclusion volunteer criteria were: the age is 20-45 years old, and the nature is not limited; oily, mixed skin, people with obvious inflammatory lesions, papules, pustules, nodules and cysts on the face; hormone drugs and immunosuppressants have not been used in the last month; the tested part does not participate in other clinical testers at present or in nearly 30 days; can be matched with testers well; the system can read and understand all contents of the informed consent and voluntarily sign the informed consent; during the test period, the consent was not to use any cosmetics, drugs and nutraceuticals that have an impact on the outcome.
Exclusion criteria: open wound or erosion face at the acne affected part; those with high allergic constitution; those with a history of cosmetic allergy; a female who is pregnant, lactating, or intended to be pregnant during the test; severe center of gravity, liver and kidney function damage and severe immunologic hypofunction; those with mental disorders, severe endocrine disorders, and oral contraceptives; the patients who participate in the drug clinical testers or other testers within 30 days, or the patients who have systemic drugs which have influence on the test results within about 1 week; those who had oral and topical cosmetic products within 2 weeks that may have an effect on the outcome of the test; the investigator considered not appropriate for attending the investigator.
Abort and exit criteria: smearing the tested sample or recording the revisit according to the requirement during the test period; has serious diseases or serious adverse reactions during the use period.
After cleaning the face in the morning and evening every day, the volunteers continuously use the corresponding essence water for 28 days. The inflammatory skin lesion repairing efficacy is clinically evaluated by a dermatologist, so that the effective number and the cure number of inflammatory skin lesion repairing are obtained. Evaluation criteria: 1) and (3) curing: disappearance of clinical symptoms, resolution of inflammatory lesions; 2) the method has the following advantages: reduction of clinical symptoms, partial regression or disappearance, reduction or reduction of inflammatory lesions; 3) and (4) invalidation: the clinical symptoms and inflammatory skin lesions are not improved. The number of effective people is recorded on the 1 st day, the 3 rd day, the 7 th day, the 14 th day and the 28 th day after the sample is tried, and the number of cured people is recorded on the 28 th day. The results are shown in Table 5 below.
TABLE 5 inflammatory skin lesion repair efficacy
As can be seen from the data in Table 5, the application examples 1 to 9 have significant efficacy of repairing inflammatory skin lesions, which is obviously superior to the application comparative examples. As can be seen from comparison between the application examples 1-9 and the application comparative examples 1-7 and the application comparative example 9, the components of the invention are combined according to a specific proportion and are matched for use, so that the synergistic effect can be achieved, the inflammatory skin injury repair time can be greatly shortened, and the cure rate is high. The number of cures using example 2, example 4 and example 5 on day 7 can be more than 20.
The technical features of the embodiments described above may be arbitrarily combined, and for the sake of brevity, all possible combinations of the technical features in the embodiments described above are not described, but should be considered as being within the scope of the present specification as long as there is no contradiction between the combinations of the technical features.
The above-mentioned embodiments only express several embodiments of the present invention, so as to understand the technical solutions of the present invention specifically and in detail, but not to be understood as the limitation of the patent protection scope of the invention. It should be noted that, for a person skilled in the art, several variations and modifications can be made without departing from the inventive concept, which falls within the scope of the present invention.
Claims (10)
1. A folic acid-containing microecological composition is characterized by comprising the following components in parts by weight:
0.01-0.3 part of folic acid and derivatives thereof;
0.09-2.7 parts of soybean fermentation product extract;
0.05-1.5 parts of alpha-glucan oligosaccharide;
0.03-0.9 part of yacon root juice;
0.01-0.3 part of inulin;
0.001-0.03 parts of lactobacillus;
0.001-0.03 part of bifidobacterium.
2. The folic acid-containing probiotic composition according to claim 1, characterized in that the folic acid and derivatives thereof are selected from one or more of folic acid, dihydrofolic acid, tetrahydrofolic acid, 5-formyltetrahydrofolic acid, 10-formyltetrahydrofolic acid, 5, 10-methenyltetrahydrofolic acid, 5, 10-methylenetetrahydrofolic acid and 5-methyltetrahydrofolic acid.
3. The folate-containing probiotic composition according to claim 1, wherein said soy fermentation product extract is selected from the group consisting of a soy fermentation product extract fermented with bacillus and/or lactobacillus.
4. The folic acid-containing microecological composition according to claim 1, wherein the lactic acid bacteria is an inactivated strain selected from one or more of Lactobacillus thermophilus, Lactobacillus casei and Lactobacillus jensenii.
5. The folic acid-containing probiotic composition according to claim 1, characterized in that said bifidobacteria are inactivated strains selected from one or more of the group consisting of bifidobacterium longum, bifidobacterium breve, bifidobacterium thermophilum and bifidobacterium ovorans.
6. The folic acid-containing microecological composition according to claim 1, which comprises 0.25 to 0.35 parts by weight of tetrahydrofolic acid, 2.6 to 2.8 parts by weight of a lactobacillus fermented soybean fermentation product extract, 1.4 to 1.6 parts by weight of alpha-glucan oligosaccharide, 0.8 to 1.0 part by weight of yacon root juice, 0.25 to 0.35 part by weight of inulin, 0.025 to 0.035 part by weight of lactobacillus casei, and 0.025 to 0.035 part by weight of bifidobacterium breve.
7. The folic acid-containing microecological composition according to claim 1, which comprises, by weight, 0.08 to 0.12 parts of folic acid, 0.8 to 1.0 part of an extract of a fermented soybean product of bacillus, 0.4 to 0.6 part of an alpha-glucan oligosaccharide, 0.25 to 0.35 part of yacon root juice, 0.08 to 0.12 part of inulin, 0.008 to 0.012 parts of lactobacillus casei, and 0.008 to 0.012 parts of bifidobacterium longum.
8. The folic acid-containing microecological composition according to claim 1, which comprises 0.18 to 0.22 part by weight of 5, 10-methenyltetrahydrofolic acid, 1.3 to 1.7 parts by weight of a lactobacillus fermented soybean fermentation product extract, 0.8 to 1.2 parts by weight of alpha-glucan oligosaccharide, 0.5 to 0.7 part by weight of yacon root juice, 0.18 to 0.22 part by weight of inulin, 0.018 to 0.022 part by weight of lactobacillus thermophilus, and 0.018 to 0.022 part by weight of bifidobacterium ovorans.
9. Cosmetic products, characterized in that they are creams, emulsions, water, oils, bathing or washing products, prepared in a versatile manner, containing a folic acid containing microecological composition according to any one of claims 1 to 8.
10. The cosmetic according to claim 9, wherein the cosmetic is essence water, and the essence water comprises, by weight, 0.15-0.25 parts of hydroxyethyl cellulose, 0.10-0.20 parts of xanthan gum, 2.5-3.5 parts of methyl propylene glycol, 0.35-0.45 parts of p-hydroxyacetophenone, 0.45-0.55 parts of 1, 2-hexanediol, the folic acid-containing microecological composition, and water.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110570106.5A CN113197837A (en) | 2021-05-25 | 2021-05-25 | Folic acid-containing microecological composition and use thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110570106.5A CN113197837A (en) | 2021-05-25 | 2021-05-25 | Folic acid-containing microecological composition and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113197837A true CN113197837A (en) | 2021-08-03 |
Family
ID=77023190
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110570106.5A Pending CN113197837A (en) | 2021-05-25 | 2021-05-25 | Folic acid-containing microecological composition and use thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113197837A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN118370693A (en) * | 2024-04-01 | 2024-07-23 | 广州梵之容化妆品有限公司 | Dispersing composition and preparation method and application thereof |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20150000025A (en) * | 2013-06-20 | 2015-01-02 | (주)다미화학 | A cosmetic composition comprising phytosphingosine-1-phosphate |
CN105796624A (en) * | 2016-05-11 | 2016-07-27 | 西安膳方医药科技有限公司 | Method for improving body surface health of living things |
CN111184681A (en) * | 2020-03-03 | 2020-05-22 | 包计贤 | Acne-blackhead-removing essence and preparation method thereof |
CN111388403A (en) * | 2020-04-12 | 2020-07-10 | 广州市索柔生物科技有限公司 | Prebiotic composition and application thereof |
CN112294719A (en) * | 2020-11-04 | 2021-02-02 | 嘉文丽(福建)化妆品有限公司 | Prebiotic composition for repairing skin barrier and application of prebiotic composition in cosmetics |
CN112535652A (en) * | 2020-09-12 | 2021-03-23 | 荣鼎(广东)生物科技有限公司 | Light sensation activation stock solution and preparation method thereof |
-
2021
- 2021-05-25 CN CN202110570106.5A patent/CN113197837A/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20150000025A (en) * | 2013-06-20 | 2015-01-02 | (주)다미화학 | A cosmetic composition comprising phytosphingosine-1-phosphate |
CN105796624A (en) * | 2016-05-11 | 2016-07-27 | 西安膳方医药科技有限公司 | Method for improving body surface health of living things |
CN111184681A (en) * | 2020-03-03 | 2020-05-22 | 包计贤 | Acne-blackhead-removing essence and preparation method thereof |
CN111388403A (en) * | 2020-04-12 | 2020-07-10 | 广州市索柔生物科技有限公司 | Prebiotic composition and application thereof |
CN112535652A (en) * | 2020-09-12 | 2021-03-23 | 荣鼎(广东)生物科技有限公司 | Light sensation activation stock solution and preparation method thereof |
CN112294719A (en) * | 2020-11-04 | 2021-02-02 | 嘉文丽(福建)化妆品有限公司 | Prebiotic composition for repairing skin barrier and application of prebiotic composition in cosmetics |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN118370693A (en) * | 2024-04-01 | 2024-07-23 | 广州梵之容化妆品有限公司 | Dispersing composition and preparation method and application thereof |
CN118370693B (en) * | 2024-04-01 | 2024-10-15 | 广州梵之容化妆品有限公司 | Dispersing composition and preparation method and application thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102105132B (en) | Cosmetic use of microorganisms for the treatment of oily skin | |
CN102131495B (en) | Microorganism is used to treat the cosmetic applications of scalp illness | |
KR101132392B1 (en) | Fermented Placenta Compositin and Use Thereof | |
CN114025778B (en) | Composition comprising the bacterial strain lactobacillus paracasei and hyaluronic acid and its use for treating skin | |
CN106794202A (en) | Improve the composition and method of human health and nutrition | |
KR101457960B1 (en) | Cosmetic composition for preventing of kin trouble | |
CN110200884B (en) | Composition with oil control and repair effects, preparation method thereof and application thereof in cosmetics | |
CN113925923B (en) | Anti-acne and whitening compound probiotic composition and preparation method thereof | |
BRPI1000537B1 (en) | COSMETIC USE OF PROBIOTIC MICROORGANISM AND COSMETIC TREATMENT PROCESS TO PREVENT AND / OR TREAT IRRITATING DERMATITIS OF NON-ALLERGIC CONTACT | |
KR20110131498A (en) | Extracted from the shell containing the antimicrobial silver ions in alkaline solution and its composition, including manufactured | |
KR101196523B1 (en) | Composition for promoting hair growth comprising fermented oriental medicine extract | |
FR2920307A1 (en) | COSMETIC USE OF MICROORGANISMS. | |
KR101253374B1 (en) | Cosmetic composition for controlling anti-acne and anti-comedo | |
TW202202156A (en) | Topical composition and its use for preparation of composition for improving skin disease and dermatitis | |
WO2005030230A1 (en) | Compositions and methods for treatment or prevention of psoriasis and related disorders | |
KR101374277B1 (en) | Composition for promoting hair growth containing fermented extracts of herb mixture | |
CN113197837A (en) | Folic acid-containing microecological composition and use thereof | |
CN111374896A (en) | Prebiotics and probiotic skin care product for treating acne and preparation method thereof | |
CN113768859A (en) | Oral and external composition for improving sensitive skin and application thereof | |
CN116407486A (en) | Active composition, cosmetic composition, application of active composition, repairing essence and preparation method of repairing essence | |
CN115414308A (en) | Acne removing composition as well as preparation method and application thereof | |
CN111601583A (en) | Cosmetic composition comprising cocoa bean hydrolysate and at least one prebiotic and probiotic | |
US11253466B2 (en) | Topical composition for rejuvenating and/or repairing skin, methods, uses and kits thereof | |
JP2017132747A (en) | Age production inhibitor | |
TWM483083U (en) | Dual sphere liposome structure of lactic acid combined with organic plant extracts for treatment and prevention of atopic dermatitis, eczema, heat rash, child diaper rash, acne and other skin inflammation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210803 |